Genetic Technologies Limited

For the year ended 30 June 2023, cash receipts were A$8.8 million, up 29% on last year. Gross margin was A$4.2 million, or 47%, and cash at bank was A$7.9 million. In the quarter, the company reported A$2.1 million in cash receipts. Management said GeneType commercial samples grew 250% versus the prior quarter. Forward-looking guidance centered on a pathway to profitability by the midpoint of FY2025, with key near-term milestones including the launch of UNITY, the hereditary breast and ovarian cancer test, and pilot programs with a payer or medical institution and with an academic institution.

Simon Morriss framed the business as moving from a long R&D phase into commercialization and then toward profitability, with a clear focus on revenue growth. He said the company’s strategy is built around GeneType, EasyDNA, and Affinity DNA, plus expansion through B2B payers, distributors, employers, and DTC channels. His tone was optimistic and execution-focused, repeatedly emphasizing the “pathway to profitability,” strong momentum, and upcoming milestones over the next 18 months.

Tony Di Pietro focused on integration, controls, and risk management rather than detailed new financial metrics. He said the two acquired businesses have been embedded into processes and reporting lines, with systems now largely in place and efficiencies being pursued across regions. On cybersecurity, he said the company has improved its security posture, especially after recent breaches in the market, and that the new businesses have moved to Office 365 while Melbourne is undergoing a similar transition.

Analysts asked how the company plans to sustain growth, and management pointed to GeneType, hereditary breast and ovarian cancer testing, and securing a major B2B payer or distributor in the U.S. as the main drivers. On payer progress, management said the company is close to finalizing the foundation for reimbursement conversations and expects a small pilot to help move discussions forward. Questions also covered ESG, direct-to-consumer execution, U.S. hiring, integration of acquisitions, cybersecurity, and the QIAGEN collaboration; management said ESG is a genuine priority, DTC website issues have been resolved, four key U.S. hires were made recently, cybersecurity has been strengthened, and QIAGEN equipment plus a new senior scientist should help bring more tests to market.